Author response for 'Benefits of insulin degludec/liraglutide (IDegLira) are maintained even in patients discontinuing sulphonylurea or dipeptidyl peptidase‐4 inhibitor upon initiation of IDegLira therapy: a post hoc analysis of the DUAL II and DUAL IX trials'

Autor:	Karolina Stachlewska, Athena Philis-Tsimikas, Liana K. Billings, Karen Salvesen-Sykes, Petra Őrsy, Andrej Janez
Rok vydání:	2019
Předmět:	business.industry Post-hoc analysis Medicine Insulin degludec / liraglutide In patient Dipeptidyl peptidase-4 inhibitor Pharmacology business medicine.drug
DOI:	10.1111/dom.13944/v2/response1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c26be6f117c8ced43ed0e68b581ebaba https://doi.org/10.1111/dom.13944/v2/response1 Zobrazit plný text záznamu